$MGTX
MeiraGTx Holdings plc Stock $mgtx

$mgtx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155837024007477 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$282.0K	$697.0K
YoY Change	-92.03%	-79.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.26M	$13.15M
YoY Change	-9.13%	2.94%
% of Gross Profit
Research & Development	$34.93M	$34.32M
YoY Change	75.22%	53.76%
% of Gross Profit
Depreciation & Amortization	$3.222M	$3.275M
YoY Change	-0.77%	5.92%
% of Gross Profit
Operating Expenses	$46.19M	$47.47M
YoY Change	42.9%	35.26%
Operating Profit	-$45.91M	-$46.77M
YoY Change	59.49%	47.27%
Interest Expense	$3.254M	$3.250M
YoY Change	-3.01%	6.21%
% of Operating Profit
Other Income/Expense, Net	-$49.00K	-$48.00K
YoY Change	4800.0%	-580.0%
Pretax Income	-$48.62M	-$20.44M
YoY Change	64.36%	-32.68%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$48.62M	-$20.44M
YoY Change	64.36%	-32.68%
Net Earnings / Revenue	-17241.13%	-2932.86%
Basic Earnings Per Share	-$0.76	-$0.32
Diluted Earnings Per Share	-$0.76	-$0.32
COMMON SHARES
Basic Shares Outstanding	64.31M	64.22M
Diluted Shares Outstanding	64.38M	64.07M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.97M	$119.2M
YoY Change	7.76%	73.3%
Cash & Equivalents	$99.97M	$119.2M
Short-Term Investments
Other Short-Term Assets	$660.0K	$932.0K
YoY Change	-57.34%	-40.29%
Inventory
Prepaid Expenses	$4.955M	$5.076M
Receivables	$1.628M	$10.92M
Other Receivables	$3.557M	$13.17M
Total Short-Term Assets	$110.8M	$149.3M
YoY Change	-22.61%	22.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$108.8M	$111.4M
YoY Change	-4.53%	-1.04%
Goodwill
YoY Change
Intangibles	$969.0K	$1.038M
YoY Change	-22.6%	-19.85%
Long-Term Investments	$6.766M	$6.766M
YoY Change	6.96%	6.96%
Other Assets	$1.139M	$1.138M
YoY Change	-22.25%	-20.31%
Total Long-Term Assets	$155.9M	$159.9M
YoY Change	-6.73%	-4.03%
TOTAL ASSETS
Total Short-Term Assets	$110.8M	$149.3M
Total Long-Term Assets	$155.9M	$159.9M
Total Assets	$266.7M	$309.2M
YoY Change	-14.06%	7.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.40M	$21.22M
YoY Change	-24.91%	-28.67%
Accrued Expenses	$16.93M	$17.35M
YoY Change	-31.99%	-44.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$47.01M	$47.54M
YoY Change	-34.53%	-41.38%
LONG-TERM LIABILITIES
Long-Term Debt	$72.67M	$72.39M
YoY Change	1.53%	1.53%
Other Long-Term Liabilities	$66.94M	$67.57M
YoY Change	55.05%	49.08%
Total Long-Term Liabilities	$139.6M	$140.0M
YoY Change	21.67%	20.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.01M	$47.54M
Total Long-Term Liabilities	$139.6M	$140.0M
Total Liabilities	$186.6M	$187.5M
YoY Change	-0.07%	-5.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$623.3M	-$574.7M
YoY Change	17.58%	14.8%
Common Stock	$3.000K	$2.000K
YoY Change	50.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$80.04M	$121.7M
YoY Change
Total Liabilities & Shareholders Equity	$266.7M	$309.2M
YoY Change	-14.06%	7.32%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$48.62M	-$20.44M
YoY Change	64.36%	-32.68%
Depreciation, Depletion And Amortization	$3.222M	$3.275M
YoY Change	-0.77%	5.92%
Cash From Operating Activities	-$19.46M	-$36.70M
YoY Change	-32.94%	-1.87%
INVESTING ACTIVITIES
Capital Expenditures	$1.329M	$1.678M
YoY Change	-73.29%	-80.5%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$29.02M
YoY Change
Cash From Investing Activities	-$1.329M	$27.34M
YoY Change	-73.29%	-417.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.603M	-1.270M
YoY Change	-97.23%	3.17%
NET CHANGE
Cash From Operating Activities	-19.46M	-36.70M
Cash From Investing Activities	-1.329M	27.34M
Cash From Financing Activities	1.603M	-1.270M
Net Change In Cash	-19.18M	-10.63M
YoY Change	-180.06%	-77.5%
FREE CASH FLOW
Cash From Operating Activities	-$19.46M	-$36.70M
Capital Expenditures	$1.329M	$1.678M
Free Cash Flow	-$20.79M	-$38.38M
YoY Change	-38.84%	-16.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2440000
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64065895
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48638151
CY2024Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://meiragtx.com/20240331#LeaseObligationsNonCurrent
CY2023Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://meiragtx.com/20240331#LeaseObligationsNonCurrent
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001735438
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63601015
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64298691
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-38520
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	MeiraGTx Holdings plc
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1448305
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	450 East 29th Street
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	14th Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10016
CY2024Q1	dei	City Area Code CityAreaCode	646
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	860-7985
CY2024Q1	dei	Security12b Title Security12bTitle	Ordinary Shares,$0.00003881 par value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	MGTX
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2440000
CY2023Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2401000
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64306613
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119206000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129566000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10915000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10138000
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5076000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5625000
CY2024Q1	us-gaap	Income Tax Receivable IncomeTaxReceivable	13171000
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	13277000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	932000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1016000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	149300000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	159622000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	111412000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	115896000
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1038000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1118000
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1059000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1083000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1138000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1917000
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	6766000
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	6766000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14835000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15910000
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	23687000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24432000
CY2024Q1	us-gaap	Assets Assets	309235000
CY2023Q4	us-gaap	Assets Assets	326744000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	21223000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16042000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17353000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42639000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4188000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4193000
CY2024Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	3772000
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	2926000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1007000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1278000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	47543000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67078000
CY2024Q1	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	53331000
CY2023Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	34017000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11796000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12952000
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	72391000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	72119000
CY2024Q1	us-gaap	Liabilities Liabilities	187501000
CY2023Q4	us-gaap	Liabilities Liabilities	188567000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00003881
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1288327750
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64298691
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63601015
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	2000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	699531000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	693841000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3126000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1435000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-574673000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-554231000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	121734000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	138177000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	309235000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	326744000
CY2024Q1	mgtx	Service Revenue From Related Parties ServiceRevenueFromRelatedParties	697000
CY2023Q1	mgtx	License Revenue From Related Parties LicenseRevenueFromRelatedParties	3334000
CY2024Q1	us-gaap	Revenues Revenues	697000
CY2023Q1	us-gaap	Revenues Revenues	3334000
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13147000
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12772000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34322000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22322000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	47469000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	35094000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-46772000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31760000
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-535000
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3857000
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1097000
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	545000
CY2024Q1	us-gaap	Interest Expense InterestExpense	3250000
CY2023Q1	us-gaap	Interest Expense InterestExpense	3060000
CY2024Q1	mgtx	Gain Loss On Sale Of Nonfinancial Assets GainLossOnSaleOfNonfinancialAssets	29018000
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	54000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20442000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30364000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1691000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2353000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22133000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32717000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36741000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37392000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20442000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30364000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64065895
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48638151
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	138177000
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4739000
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1586000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	635000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1691000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20442000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	121734000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117738000
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5201000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2353000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30364000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	90222000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-20442000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-30364000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6960000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6432000
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-535000
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3857000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3275000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3092000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-36000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-24000
CY2024Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	48000
CY2023Q1	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	44000
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	273000
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	266000
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	54000
CY2024Q1	mgtx	Gain Loss On Sale Of Nonfinancial Assets GainLossOnSaleOfNonfinancialAssets	29018000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1603000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	14137000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-530000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1235000
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-626000
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-136000
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-632000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5198000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	14642000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-24231000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11469000
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	37000
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20475000
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3334000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1678000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8605000
CY2024Q1	mgtx	Proceeds From Gain On Sale Of Nonfinancial Assets ProceedsFromGainOnSaleOfNonfinancialAssets	29018000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27340000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8605000
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2221000
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1231000
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1586000
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	635000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1270000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1231000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10671000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-47228000
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	287000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	496000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130649000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115516000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120265000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68784000
CY2024Q1	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	1558000
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	3162000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	2953000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1572000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-574700000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36700000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120300000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, fair value of nonfinancial assets, stand-alone selling price and material rights in connection with the Asset Purchase and Supply Agreements, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations, fair value of financial instruments and tax incentive receivable.</p>
CY2024Q1	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	6665000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119206000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	129566000
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1059000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1083000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120265000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130649000
CY2023Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2401000
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2179000
CY2024Q1	mgtx	Asset Retirement Obligations Amortization Of Interest AssetRetirementObligationsAmortizationOfInterest	48000
CY2023Q1	mgtx	Asset Retirement Obligations Amortization Of Interest AssetRetirementObligationsAmortizationOfInterest	44000
CY2024Q1	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	-9000
CY2023Q1	us-gaap	Asset Retirement Obligation Foreign Currency Translation Gain Loss AssetRetirementObligationForeignCurrencyTranslationGainLoss	15000
CY2023Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	2238000
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13464394
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11796179
CY2024Q1	us-gaap	Noncurrent Assets NoncurrentAssets	150972000
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	157356000
CY2024Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	6766000
CY2024Q1	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	5610000
CY2023Q4	mgtx	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	8713000
CY2024Q1	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	2646000
CY2023Q4	mgtx	Accrued Research And Development AccruedResearchAndDevelopment	5834000
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2424000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6499000
CY2024Q1	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	1966000
CY2023Q4	mgtx	Accrued Consulting Expenses AccruedConsultingExpenses	2104000
CY2024Q1	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	1961000
CY2023Q4	mgtx	Accrued Liabilities Accrued Compensation And Benefits AccruedLiabilitiesAccruedCompensationAndBenefits	12129000
CY2024Q1	mgtx	Accrued Liabilities Accrued Manufacturing Costs Expense AccruedLiabilitiesAccruedManufacturingCostsExpense	1804000
CY2023Q4	mgtx	Accrued Liabilities Accrued Manufacturing Costs Expense AccruedLiabilitiesAccruedManufacturingCostsExpense	2634000
CY2024Q1	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	641000
CY2023Q4	mgtx	Accrued Expenses Incurred In Connection With Fixed Assets AccruedExpensesIncurredInConnectionWithFixedAssets	1472000
CY2024Q1	mgtx	Accrued Expenses Incurred In Connection With Rent And Facility Costs AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts	138000
CY2023Q4	mgtx	Accrued Expenses Incurred In Connection With Rent And Facility Costs AccruedExpensesIncurredInConnectionWithRentAndFacilityCosts	142000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	176000
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	2936000
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17353000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42639000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8226707
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.96
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	365100
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.16
CY2023Q1	us-gaap	Lease Cost LeaseCost	1681000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	107163
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.00
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8484644
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.65
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M1D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6203005
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.13
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8484644
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.65
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M1D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1406
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1406
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4300000
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6200000
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6200000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.77
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6960000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6432000
CY2024Q1	mgtx	Modifications To Share Based Compensation ModificationsToShareBasedCompensation	0
CY2023Q1	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
CY2024Q1	mgtx	Excess Tax Benefit From Share Based Compensation Operating Activities1 ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1	0
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14835000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15910000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	15984000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17145000
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	23687000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24432000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P174Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P174Y9M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024Q1	mgtx	Gain Loss On Sale Of Nonfinancial Assets GainLossOnSaleOfNonfinancialAssets	29000000.0
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	281000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	281000
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	281000
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	281000
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1437000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1361000
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	41000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	39000
CY2024Q1	us-gaap	Lease Cost LeaseCost	1759000
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1419000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1384000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4117000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5495000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5585000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1608000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1319000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	691000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	18815000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2831000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	15984000
CY2024Q1	mgtx	Number Of New Material Commitments NumberOfNewMaterialCommitments	0
CY2024Q1	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	March 21, 2024
CY2024Q1	ecd	Trd Arr Ind Name TrdArrIndName	Alexandria Forbes, Ph.D.
CY2024Q1	ecd	Trd Arr Ind Title TrdArrIndTitle	President and Chief Executive Officer
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	190000

Files In Submission

Name	View Source	Status
0001558370-24-007477-index-headers.html	Edgar Link	pending
0001558370-24-007477-index.html	Edgar Link	pending
0001558370-24-007477.txt	Edgar Link	pending
0001558370-24-007477-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgtx-20240331.xsd	Edgar Link	pending
mgtx-20240331x10q.htm	Edgar Link	pending
mgtx-20240331xex31d1.htm	Edgar Link	pending
mgtx-20240331xex31d2.htm	Edgar Link	pending
mgtx-20240331xex32d1.htm	Edgar Link	pending
mgtx-20240331xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
mgtx-20240331_cal.xml	Edgar Link	unprocessable
mgtx-20240331x10q_htm.xml	Edgar Link	completed
mgtx-20240331_def.xml	Edgar Link	unprocessable
mgtx-20240331_pre.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mgtx-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGTX
MeiraGTx Holdings plc Stock $mgtx

2024 Q2 Form 10-Q Financial Statement

#000155837024007477 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGTX MeiraGTx Holdings plc Stock $mgtx

2024 Q2 Form 10-Q Financial Statement

#000155837024007477 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGTX
MeiraGTx Holdings plc Stock $mgtx